Scancell : Interim Report 31st October 2023
CHIEF EXECUTIVE OFFICER'S STATEMENT I am pleased to report the Group's interim results for the six-month period ended 31 October 2023. During the period, Scancell...
Stay updated with breaking news from Derivative Liabilities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHIEF EXECUTIVE OFFICER'S STATEMENT I am pleased to report the Group's interim results for the six-month period ended 31 October 2023. During the period, Scancell...
Full Year Revenue was $160.8 million, up 89% year-over-year Q4 Revenue was $40.4 million, exceeding guidance and up 35% year-over-year Adjusted EBITDA1 was...
Fourth quarter performance delivered highest revenue and gross margin for the yearRecord cash flow from operations of $202 million and free cash flow of $161 million* in 2023Expect 2024 cash
NEW YORK, Dec. 11, 2023 -- Balincan USA Inc. and Tekumo announces a record progress update for Q4, 2023. Revenue for the first two months of the fourth quarter was $850K, a record in each...
NEW YORK, Nov. 21, 2023 -- Balincan USA Inc. and Tekumo announced its financial results for the third quarter. Revenue for the third quarter increased a record 194% over the second...